Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Needham analyst Serge Belanger has reiterated a Buy rating on Ocular Therapeutix (NASDAQ: OCUL) and maintained a price target of $18 for the company's stock. No additional financial figures or strategic changes were mentioned in the article.